ArticleAnnals of hematology2026
Flow cytometric analysis of T-cell subsets and platelet surface markers in patients with immune thrombocytopenia: a case-control study.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by increased platelet destruction and impaired platelet production. The role of T-cell subsets and platelet surface markers in ITP pathogenesis remains incompletely understood. To evaluate T-cell subpopulations and platelet surface marker expression in patients with chronic ITP compared with healthy controls using flow cytometry. This prospective case-control study included 26 chronic ITP patients and 25 healthy controls from the Hematology Department of Mersin University Hospital. Flow cytometric analysis was performed to assess CD3+, CD4+, CD8+, CD25+, CD45RA+, CD62L-, and platelet surface markers including CD41, CD42, and CD61. Statistical analyses were performed using SPSS version 22. ITP patients demonstrated significantly lower platelet counts (97,038 ± 64,596 vs. 256,920 ± 48,873/µL, p < 0.001) and higher mean platelet volume values (11.67 ± 1.46 vs. 10.46 ± 0.77 fL, p = 0.001) compared with healthy controls. CD45RA+/CD4 + ratios were significantly lower in ITP patients (10.52 ± 5.88 vs. 14.45 ± 7.21%, p = 0.038). CD62L- expression was also decreased in the ITP group (51.50 ± 12.16 vs. 60.68 ± 8.40%, p = 0.003). Among platelet surface markers, CD41 and CD61 expressions were significantly reduced in ITP patients compared with controls (p < 0.001 for both). Although CD42 expression did not differ significantly between the overall groups, subgroup analysis demonstrated significantly lower CD42 expression in patients with platelet counts below 30,000/µL (p < 0.001). This study demonstrates alterations in T-cell differentiation markers and platelet surface glycoproteins in patients with chronic ITP. Reduced CD45RA+/CD4 + ratios, altered CD62L expression, and decreased CD41 and CD61 levels suggest ongoing immune dysregulation and abnormal platelet biology in these patients. Further longitudinal and functional studies are needed to clarify the mechanistic and clinical significance of these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.